HLA-A24 and Survivin: Possibilities in Therapeutic Vaccination Against Cancer

Journal of Translational Medicine - United Kingdom
doi 10.1186/1479-5876-4-38
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Randomized Phase II Trial of Survivin 2B Peptide Vaccination for Patients With HLA-A24-positive Pancreatic Adenocarcinoma

Cancer Science
Cancer ResearchMedicineOncology
2019English

Therapeutic Cancer Vaccines and Combination Immunotherapies Involving Vaccination

ImmunoTargets and Therapy
AllergyImmunology
2014English

Therapeutic Vaccination Against Autologous Cancer Stem Cells With mRNA-transfected Dendritic Cells in Patients With Glioblastoma

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2013English

The Delivery of Effective Therapeutic Cancer Vaccination

Asian Journal of Andrology
MedicineUrology
2010English

Identification of Squamous Cell Carcinoma Antigen-Derived Peptides Having the Capacity of Inducing Cancer-Reactive CTLs in HLA-A24+ Cancer Patients

International Journal of Oncology
Cancer ResearchOncology
2006English

Identification of a Novel HLA-A24-restricted Cytotoxic T Lymphocyte Epitope Peptide Derived From Mesothelin in Pancreatic Cancer

Oncotarget
Oncology
2018English

XIAP and Survivin as Therapeutic Targets for Radiation Sensitization in Preclinical Models of Lung Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2004English

Treg Inducing Adjuvants for Therapeutic Vaccination Against Chronic Inflammatory Diseases

Frontiers in Immunology
AllergyImmunology
2013English

Delivery of a Survivin Promoter-Driven Antisense Survivin-Expressing Plasmid DNA as a Cancer Therapeutic: A Proof-Of-Concept Study

OncoTargets and Therapy
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy